SAN FRANCISCO--(BUSINESS WIRE)--Through integration with Multiply Labs' robotic technology, Thermo Fisher Scientific’s advanced, industry-leading cell therapy instruments, including the Thermo Scientific™ Heracell™ VIOS Automated Access CO2 Incubator and the Gibco™ Cell Therapy Systems (CTS™) Rotea™ Counterflow Centrifugation System can now be fully automated for cell therapy manufacturing.

旧金山--（商业新闻短讯）--通过与Multiply Labs的机器人技术集成，Thermo Fisher Scientific的先进、业界领先的细胞治疗仪器，包括Thermo Scientific™Heracell™VIOS自动获取二氧化碳培养箱和Gibco™细胞治疗系统（CTS™）Rotea™逆流离心系统现在可以完全自动化用于细胞治疗制造。

This collaboration is an important step forward for cell therapy development and manufacturing with a goal of supporting reduced costs, accelerated production timelines and improved scalability, helping innovative cell therapies reach more patients..

这种合作是细胞疗法开发和制造向前迈出的重要一步，旨在支持降低成本，加快生产时间表和提高可扩展性，帮助创新细胞疗法惠及更多患者。。

With the automated Heracell VIOS Incubator, up to 18 products can be hosted in parallel when using G-Rex100M bioreactors. This is a steep increase over traditional manual manufacturing, where one or two G-Rex100M bioreactors are used in parallel in a single incubator. The ability to support 18 products at once per incubator signals future scalability, as with two automated incubators, manufacturers would be able to create 36 products at the same time and scale upwards from there as incubators are added..

使用自动Heracell VIOS培养箱，当使用G-Rex100M生物反应器时，最多可以并行托管18种产品。与传统的手工制造相比，这是一个急剧的增长，传统的手工制造在单个培养箱中并行使用一个或两个G-Rex100M生物反应器。每个孵化器一次支持18种产品的能力标志着未来的可扩展性，就像两个自动化孵化器一样，制造商将能够同时创建36种产品，并随着孵化器的增加而扩大规模。。

Furthermore, by automating Thermo Fisher’s CTS Rotea Counterflow Centrifugation System, key manufacturing steps including upstream and downstream cell processing, can be performed automatically. Therefore, automation supports not only increased throughput but also lower labor cost, as these important processes can be executed by a single manufacturing operator.

此外，通过自动化Thermo Fisher的CTS Rotea逆流离心系统，可以自动执行包括上游和下游细胞处理在内的关键制造步骤。因此，自动化不仅可以提高吞吐量，还可以降低劳动力成本，因为这些重要过程可以由单个制造操作员执行。

For comparison, traditional manual manufacturing processes typically require 4-8 operators. An end-to-end automated workflow using robotic technology only requires 400-500 sq ft of space compared to the 1000-2000 sq ft of space required for human-operated workflows..

相比之下，传统的手工制造过程通常需要4-8名操作员。使用机器人技术的端到端自动化工作流程只需要400-500平方英尺的空间，而人工操作的工作流程需要1000-2000平方英尺的空间。。

Xavier De Mollerat Du Jeu, Senior Director of Research and Development at Thermo Fisher Scientific, expressed excitement about the expanded partnership, emphasizing its significance in delivering curative therapies to patients more efficiently. “With so many groundbreaking cell therapies available or forthcoming for patients, we cannot afford to let manual processes reduce scalability and stand in the way of access.

Thermo Fisher Scientific研发高级总监Xavier De Mollerat Du Jeu对扩大的合作关系表示兴奋，强调其在更有效地为患者提供治疗方面的重要性。“有这么多开创性的细胞疗法可用于或即将用于患者，我们不能让手动过程降低可扩展性并阻碍访问。

Not only are we taking our incubator partnership to the next level to deliver a fully-automated GMP product, but together we will engineer the automation of our latest-generation closed system centrifuge – an essential instrument for cell therapy manufacturing,” he added..

我们不仅将孵化器合作关系提升到一个新的水平，以提供全自动GMP产品，而且我们将共同设计最新一代封闭系统离心机的自动化，这是细胞治疗制造的重要工具，”他补充道。。

Cell therapy innovators and CDMOs can benefit from this collaboration by integrating Thermo Fisher's top-notch solutions while enjoying the advantages of automation, such as cost reduction and increased throughput. Multiply Labs recently demonstrated that automated and manual cell expansion processes are statistically equivalent.

细胞疗法创新者和CDMOs可以通过整合Thermo Fisher的一流解决方案而受益于这种合作，同时享受自动化的优势，例如降低成本和提高吞吐量。Multiply实验室最近证明，自动和手动细胞扩增过程在统计学上是等效的。

This implies that manufacturers can automate their current cell expansion protocols with minimal alterations and reduced regulatory risk..

这意味着制造商可以自动化其当前的细胞扩增协议，只需进行最小的更改并降低监管风险。。

Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs, expressed enthusiasm about the collaboration's potential impact on cell therapy manufacturing. “The goal is to establish a seamlessly automated, plug-and-play process that positively influences patient care. The ongoing partnership with Thermo Fisher plays a crucial role in turning this vision into reality, advancing the realization of cell therapy for the benefit of patients.”.

Fred Parietti博士，Multiply Labs联合创始人兼首席执行官，对该合作对细胞治疗制造业的潜在影响表示热情。“目标是建立一个无缝自动化的即插即用流程，对患者护理产生积极影响。与Thermo Fisher的持续合作在将这一愿景变为现实，推动实现细胞治疗以造福患者方面发挥着至关重要的作用。”。

About Multiply Labs

关于Multiply Labs

Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space.

Multiply Labs是一家机器人公司，为制药行业提供自主制造技术。该公司开发了先进的云控制机器人系统，可以大规模生产个性化药物。其客户包括先进制药制造领域的一些最大的全球组织。

Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California.

Multiply Labs的专业知识是机器人技术和生物制药的交叉点，其团队包括机械工程师、电气工程师、计算机科学家、软件工程师和制药科学家。创始团队之所以取得联系，是因为他们在麻省理工学院共同热爱机器人。该公司总部位于加利福尼亚州旧金山。

For more information, please visit www.multiplylabs.com..

有关更多信息，请访问www.multiplylabs.com。。